Should I buy or sell Pulmatrix stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares. View PULM analyst ratings or view top-rated stocks .

What is Pulmatrix's stock price target for 2024?

1 brokers have issued 1 year price objectives for Pulmatrix's stock. Their PULM share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 402.5% from the stock's current price. View analysts price targets for PULM or view top-rated stocks among Wall Street analysts .

How have PULM shares performed in 2024?

Pulmatrix's stock was trading at $1.86 at the start of the year. Since then, PULM stock has increased by 7.0% and is now trading at $1.99. View the best growth stocks for 2024 here .

Are investors shorting Pulmatrix?

Pulmatrix saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,700 shares, an increase of 575.0% from the March 15th total of 400 shares. Based on an average trading volume of 16,100 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are short sold. View Pulmatrix's Short Interest .

When is Pulmatrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our PULM earnings forecast .

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) issued its quarterly earnings results on Thursday, March, 28th. The biotechnology company reported ($0.57) EPS for the quarter. The biotechnology company had revenue of $2.20 million for the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 63.94% and a negative net margin of 193.49%.

When did Pulmatrix's stock split?

Shares of Pulmatrix reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Acasti Pharma (ACST) , Biocept (BIOC) , Heat Biologics (HTBX) , Trevena (TRVN) , TherapeuticsMD (TXMD) , Verastem (VSTM) and Evoke Pharma (EVOK) .

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PULM

Pulmatrix (PULM) Stock Price, News & Analysis

→ Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad)

Free PULM Stock Alerts

$1.99

+0.03 (+1.53%)

(As of 12:18 PM ET)

Compare

Today's Range: $1.91
▼
$2.04
50-Day Range: $1.62
▼
$2.16
52-Week Range: $1.55
▼
$3.14

Volume: 11,088 shs
Average Volume: 18,154 shs
Market Capitalization: $7.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Pulmatrix alerts:

Pulmatrix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 402.5% Upside
$10.00 Price Target
Short Interest: Healthy
0.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.94 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Pulmatrix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Pulmatrix has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.07% of the float of Pulmatrix has been sold short.
Short Interest Ratio / Days to Cover
Pulmatrix has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pulmatrix has recently increased by 575.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Pulmatrix does not currently pay a dividend.
Dividend Growth
Pulmatrix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PULM.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Pulmatrix this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for PULM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pulmatrix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.61% of the stock of Pulmatrix is held by insiders.
Percentage Held by Institutions
Only 11.84% of the stock of Pulmatrix is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Pulmatrix is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pulmatrix is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pulmatrix has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

About Pulmatrix Stock (NASDAQ:PULM)

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

PULM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PULM Stock News Headlines

April 16, 2024 | americanbankingnews.com

Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com

March 28, 2024 | investorplace.com

PULM Stock Earnings: Pulmatrix Beats EPS, Beats Revenue for Q4 2023

April 19, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

March 28, 2024 | finanznachrichten.de

Pulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

March 28, 2024 | prnewswire.com

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

February 15, 2024 | morningstar.com

Cipla Ltd CIPLA

January 10, 2024 | bizjournals.com

Five things: Boston State of the City, high business costs, biotech shutdowns and Boston Calling headliners

January 9, 2024 | bizjournals.com

Pulmatrix shuts down study, explores sale

April 19, 2024 | Timothy Sykes (Ad)

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

January 8, 2024 | nasdaq.com

Pulmatrix To Stop PUR1900 Phase 2B Study Patient Enrollment And Closing The Study

January 8, 2024 | marketwatch.com

Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives

January 8, 2024 | finance.yahoo.com

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

January 8, 2024 | msn.com

Stocks in news: Titan, Marico, Bajaj Auto, Adani Wilmar, Tata Steel

January 8, 2024 | msn.com

Stock Market Today: Dr Reddy's, Titan, And Reliance Power Shares In Focus

November 12, 2023 | morningstar.com

Pulmatrix Inc PULM

November 9, 2023 | baystreet.ca

Pulmatrix Down on Q3 Results

November 9, 2023 | msn.com

Pulmatrix GAAP EPS of -$1.03, revenue of $1.75M

November 9, 2023 | finance.yahoo.com

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

October 23, 2023 | finance.yahoo.com

Aspergillosis Treatment Research Report 2023

September 19, 2023 | markets.businessinsider.com

Pulmatrix Receives Study May Proceed Letter From FDA For Phase 2 Study To Evaluate PUR3100

September 19, 2023 | finance.yahoo.com

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

September 11, 2023 | msn.com

Pulmatrix, Inc. (PULM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 23, 2023 | finance.yahoo.com

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

August 10, 2023 | finanznachrichten.de

Pulmatrix, Inc.: Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 10, 2023 | msn.com

Pulmatrix GAAP EPS of -$1.04, revenue of $1.84M

August 10, 2023 | finance.yahoo.com

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 11, 2023 | finance.yahoo.com

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

See More Headlines

Receive PULM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmatrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PULM
CUSIP: N/A
CIK: 1574235
Web: www.pulmatrix.com
Phone: (781) 357-2333
Fax: 707-525-9906
Employees: 28
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +412.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,120,000.00
Net Margins: -193.49%
Pretax Margin: -193.49%
Return on Equity: -63.94%
Return on Assets: -40.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.33
Quick Ratio: 5.33

Sales & Book Value

Annual Sales: $7.30 million
Price / Sales: 0.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.93 per share
Price / Book: 0.40

Miscellaneous

Outstanding Shares: 3,650,000
Free Float: 3,520,000
Market Cap: $7.12 million
Optionable: Not Optionable
Beta: 0.92

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Teofilo David Raad MBA (Age 54)
President, CEO & Director
Comp: $772.7k
Mr. Peter Ludlum CMA (Age 69)
MBA, Interim CFO and Principal Accounting & Financial Officer
Comp: $398.58k
Dr. Alexander M. Klibanov Ph.D. (Age 74)
Founder

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PULM Stock Analysis - Frequently Asked Questions

Should I buy or sell Pulmatrix stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PULM shares.
View PULM analyst ratings or view top-rated stocks.
What is Pulmatrix's stock price target for 2024?: 1 brokers have issued 1 year price objectives for Pulmatrix's stock. Their PULM share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 402.5% from the stock's current price.
View analysts price targets for PULM or view top-rated stocks among Wall Street analysts.
How have PULM shares performed in 2024?: Pulmatrix's stock was trading at $1.86 at the start of the year. Since then, PULM stock has increased by 7.0% and is now trading at $1.99.
View the best growth stocks for 2024 here.
Are investors shorting Pulmatrix?: Pulmatrix saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,700 shares, an increase of 575.0% from the March 15th total of 400 shares. Based on an average trading volume of 16,100 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are short sold.
View Pulmatrix's Short Interest.
When is Pulmatrix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our PULM earnings forecast.

How were Pulmatrix's earnings last quarter?: Pulmatrix, Inc. (NASDAQ:PULM) issued its quarterly earnings results on Thursday, March, 28th. The biotechnology company reported ($0.57) EPS for the quarter. The biotechnology company had revenue of $2.20 million for the quarter. Pulmatrix had a negative trailing twelve-month return on equity of 63.94% and a negative net margin of 193.49%.
When did Pulmatrix's stock split?: Shares of Pulmatrix reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Pulmatrix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Acasti Pharma (ACST), Biocept (BIOC), Heat Biologics (HTBX), Trevena (TRVN), TherapeuticsMD (TXMD), Verastem (VSTM) and Evoke Pharma (EVOK).
How do I buy shares of Pulmatrix?: Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PULM) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pulmatrix (PULM) Stock Price, News & Analysis

Pulmatrix MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Pulmatrix Stock (NASDAQ:PULM)

PULM Stock Price History

PULM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PULM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™